The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

Topics presented at the conference include the tumor microenvironment, metabolic influences, immune effects, and more.

Jason Aboudi Mouabbi, MD, discusses neoadjuvant multi-agent chemotherapy in HER2+ breast cancer.

Luis E. Raez, MD, and Suresh S. Ramalingam, MD, FACP, FASCO, sit down with Chandler Park, MD, FACP, and Eric K. Singhi, MD, to discuss the latest abstracts in lung cancer presented during the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer.

Ghayas C. Issa, MD, MS, discusses the optimal timing of and approaches to genetic testing for NPM1 and KMT2A alterations in AML.

Sanam Loghavi, MD, discusses standard-of-care frontline testing in myelodysplastic syndrome.

First-line venetoclax plus azacitidine did not improve overall survival vs placebo plus azacitidine in treatment-naive, higher-risk MDS.

Dr Kopetz discusses the value of ctDNA assays, trials that have shown prognostic implications with this type of assay, and the future of ctDNA research.

Here is your guide to all therapeutic options that were cleared by the FDA in August 2025 spanning tumor types.

A study finds cancer cells break down protective nerve coverings, leading to nerve injury and chronic inflammation.

The MD Anderson Cancer Center was ranked number one in the nation for cancer care in U.S. News & World Report’s 2024-25 "Best Hospitals" survey.

Tina Cascone, MD, PhD, discusses of perioperative nivolumab vs placebo in patients with resectable non–small cell lung cancer.

Collaboration will aim to obtain CAP/CLIA certification of organoid-based assay, followed by clinical studies in multiple indications

Guillermo Garcia-Manero, MD, discusses the integration of luspatercept into real-world practice in ESA-naive, lower-risk MDS.

Oncology experts share topline insights from 19 of the most exciting abstracts from the 2025 ASCO Annual Meeting.

Dr Kuerer discusses the potential to omit surgery in patients with HER2-positive or triple-negative breast cancer who have pCR after neoadjuvant therapy.

Researchers found potential biomarkers that can highly predict which patients with stage III melanoma have better outcomes or are at high risk of recurrence.

Guillermo Garcia-Manero, MD, highlights clinical trial findings and real-world data for luspatercept in ESA-naive, lower-risk MDS.

Studies have suggested that pre-surgical SRT may be comparable to standard post-surgical SRT in patients with resectable brain metastases.

Guillermo Garcia-Manero, MD, discusses OS data from the COMMANDS trial for luspatercept in ESA-naive, lower-risk MDS.

Acalabrutinib plus BR prolonged duration of MRD negativity vs BR alone in previously untreated MCL, supporting the use of MRD as a prognostic biomarker.

Ibrutinib plus venetoclax led to complete responses and durable remissions in the first-line treatment of older patients with MCL.

Guillermo Garcia-Manero, MD, highlights recent shifts in the lower-risk myelodysplastic syndrome treatment paradigm.

MD Anderson researchers are enhancing CD19 CAR T-cell therapy outcomes in LBCL through precision medicine insights.

Researchers at MD Anderson Cancer Center have identified a novel target for high-risk multiple myeloma.

Lung cancer patients with high TTF-1 expression had improved survival outcomes following treatment with the KRAS inhibitor, sotorasib.

David S. Hong, MD, discusses the full FDA approval of larotrectinib for NTRK fusion–positive solid tumors.

CPRIT awards over $21 million to MD Anderson for cancer research and faculty recruitment.

The top 5 OncLive videos of the week cover insights in ovarian cancer, prostate cancer, chronic lymphocytic leukemia, and breast cancer.